Dermira to Present at 17th Annual Needham Healthcare Conference
March 20, 2018 08:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2018 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Cowen & Company 38th Annual Healthcare Conference
March 08, 2018 08:00 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 05, 2018 07:59 ET
|
Dermira, Inc.
Company expects to discontinue the programConference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT MENLO PARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM),...
Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
February 22, 2018 16:01 ET
|
Dermira, Inc.
Olumacostat glasaretil topline Phase 3 data expected Q1 2018FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018Lebrikizumab Phase 2b study enrolling patients and...
New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
February 17, 2018 18:30 ET
|
Dermira, Inc.
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new...
Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
February 12, 2018 08:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018 08:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 08, 2018 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
January 31, 2018 08:30 ET
|
Dermira, Inc.
Study expected to enroll approximately 275 patientsTopline results expected in the first half of 2019TREBLE Phase 2 proof-of-concept results published in the Journal of the American Academy of...